依帕司他与匹维溴铵辅治糖尿病性肠病的效果及对血清GLP-1、MTL、SP水平的影响  

Therapeutic efficacy of epalrestat and pinaverium bromide on diabetes enteropathy as an adjuvant treatment and their regulatory effects on serum levels of glucagon-like peptide-1,motilin and substance P

作　　者：陶赟臻 赵晓秋 任素霞 冀美佳 陈丽萍 TAO Yunzhen;ZHAO Xiaoqiu;REN Suxia(First Department of Geriatrics,Zhangjiakou First Hospital,Hebei,Zhangjiakou 075000,China;不详)

机构地区：[1]河北省张家口市第一医院老年病一科,075000 [2]河北省张家口市第一医院呼吸与危重症一科 [3]河北省张家口市第二医院内科

出　　处：《河北医药》2023年第12期1798-1802,共5页Hebei Medical Journal

基　　金：张家口市市级科技计划自筹经费项目(编号:1921088D)。

摘　　要：目的研究依帕司他与匹维溴铵辅治糖尿病性肠病(DE)的疗效及对血清胰高血糖素样肽-1(GLP-1)、胃动素(MTL)、P物质(SP)水平的影响。方法选择2019年1月至2020年9月糖尿病性肠病患者102例作为研究对象,采用数字表随机法分为2组。对照组51例患者给予胰岛素联合甲钴胺治疗,观察组51例患者在此基础上给予依帕司他片、匹维溴铵片辅助治疗,治疗前、治疗后3个月抽取空腹静脉血检测血清GLP-1、MTL、SP水平,评价疗效。结果观察组总有效率为88.24%,高于对照组的64.71%,差异有统计学意义(P<0.05)。治疗后2组腹泻严重程度评分、自主排便频率评分、排便困难程度评分较治疗前明显降低,差异有统计学意义(P<0.05)。观察组治疗后腹泻严重程度评分、自主排便频率评分、排便困难程度评分均低于对照组[(0.86±0.17)vs(1.51±0.28)]分、[(0.72±0.19)vs(1.62±0.27)]分、[(0.55±0.08)vs(1.34±0.17)]分,差异有统计学意义(P<0.05)。治疗后2组FGLP-1、2hGLP-1、SP水平较治疗前明显升高,MTL水平较治疗前明显降低,差异有统计学意义(P<0.05)。观察组治疗后FGLP-1、2hGLP-1、SP水平均高于对照组[(28.69±3.96)vs(24.82±3.52)]pmol/L、[(29.53±3.07)vs(25.14±2.83)]pmol/L、[(33.59±3.06)vs(25.73±2.64)]pg/ml,MTL水平低于对照组[(116.47±17.26)vs(153.82±21.25)]pg/ml,差异有统计学意义(P<0.05)。结论依帕司他与匹维溴铵辅治DE可调节患者血清GLP-1、MTL、SP水平,促进胃肠功能恢复,进一步改善临床症状,提高疗效。Objective To analyze the therapeutic efficacy of epalrestat and pinaverium bromide on diabetic enteropathy(DE),and their influences on serum levels of glucagon-like peptide-1(GLP-1),motilin(MTL)and substance P(SP).Methods From January 2019 to September 2020,102 patients with DE admitted in our hospital were selected as the research objects,and they were randomly divided into two groups using a digital table.A total of 51 patients in the control group were treated with insulin combined with mecobalamin,and 51 patients were given insulin combined with mecobalamin,as well as an adjuvant treatment with epalrestat tablets and pinaverium bromide tablets.Fasting venous blood was drawn before and 3 months after treatment to detect serum levels of GLP-1,MTL,and SP to evaluate the therapeutic efficacy.Results The overall effective rate in the observation group was significantly higher than that in the control group(88.24%vs 64.71%,P<0.05).After treatment,the diarrhea severity score,spontaneous defecation frequency score,and defecation difficulty score in both groups were significantly reduced compared with those before treatment(P<0.05).The diarrhea severity score([0.86±0.17]points vs[1.51±0.28]points),spontaneous defecation frequency score(0.72±0.19 vs 1.62±0.27)and defecation difficulty score([0.55±0.08]vs[1.34±0.17])after treatment in the observation group were significantly lower than those in the control group(all P<0.05).After treatment,serum levels of fasting GLP-1(FGLP-1),GLP-1 at 2h(2hGLP-1)and SP in both groups were significantly higher than those before treatment,and the level of MTL was significantly lower than that before treatment(P<0.05).After treatment,the levels of FGLP-1([28.69±3.96]pmol/L vs[24.82±3.52]pmol/L),2hGLP-1([29.53±3.07]pmol/L vs[25.14±2.83]pmol/L)and SP([33.59±3.06]pg/ml vs[25.73±2.64]pg/ml)in the observation group were significantly higher than those in the control group,while the MTL level was significantly lower([116.47±17.26]pg/ml vs[153.82±21.25]pg/ml)(all P<0.05).Conclusion

关 键 词：依帕司他 匹维溴铵 糖尿病性肠病 胰高血糖素样肽-1 胃动素 P物质 

分 类 号：R587.29[医药卫生—内分泌]